- Report
- May 2025
- 175 Pages
Global
From €3956EUR$4,490USD£3,432GBP
- Report
- February 2025
- 200 Pages
Global
From €3956EUR$4,490USD£3,432GBP
- Report
- June 2025
- 400 Pages
Global
From €4361EUR$4,949USD£3,782GBP
- Report
- May 2024
- 200 Pages
Global
From €3657EUR$4,150USD£3,172GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4361EUR$4,950USD£3,783GBP
- Report
- February 2023
- 234 Pages
Global
From €2203EUR$2,500USD£1,911GBP
- Book
- December 2022
- 1376 Pages
- Book
- April 2020
- 342 Pages
- Book
- December 2018
North America
- Book
- August 2018
Asia Pacific
Lupus Nephritis is a type of kidney disease caused by systemic lupus erythematosus (SLE). It is a common complication of SLE and is one of the leading causes of end-stage renal disease. In the context of Urology and Nephrology, Lupus Nephritis is a major area of research and treatment. It is a complex condition that requires a multidisciplinary approach, including nephrologists, rheumatologists, and other specialists. Treatment options include immunosuppressive medications, such as corticosteroids, and biologic agents. In some cases, kidney transplantation may be necessary.
Companies in the Lupus Nephritis market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Pfizer, and Roche. Show Less Read more
